AMTAGVI® (lifileucel) Label Expansion
Product Candidate
Indication(s)
Phase 1
Phase 2
Phase 3
Lifileucel + pembro
Frontline advanced melanoma
Phase 1
Phase 2
Phase 3
TILVANCE-301 (FTD, Confirmatory)
Lifileucel
Post-chemo & anti-PD-1 advanced NSCLC
Phase 1
Phase 2
Phase 3
IOV-LUN-202 (FTD)
Lifileucel
Post-chemo advanced soft tissue sarcomas (DDLPS or UPS)
Phase 1
Phase 2
Phase 3
SARATOGA (FTD)
Lifileucel
Post-chemo & anti-PD-1 endometrial cancer
Phase 1
Phase 2
Phase 3
IOV-END-201
Next Generation Products
Product Candidate
Indication(s)
Phase 1
Phase 2
Phase 3
IOV-4001 (PD-1 Inactivated TIL)
Post anti-PD-1 advanced melanoma or NSCLC
Phase 1
Phase 2
Phase 3
IOV-GM1-201
IOV-3001 (IL-2 analog)
TIL treatment regimen
Phase 1
Phase 2
Phase 3
IOV-IL2-101
IOV-5001 (IL-12 tethered TIL)
Post-ICI CRC, TNBC/ER Low, HNSCC, NSCLC
Phase 1
Phase 2
Phase 3
IOV-GE1-201

2L, second line; 4L, fourth line; CRC, colorectal cancer; DDLPS, dedifferentiated liposarcoma; ER, estrogen-receptor; FTD, Fast Track Designation; IO, immuno-oncology; HNSCC, head and neck squamous cell carcinoma; IL-2, interleukin 2; IL-12, interleukin 12; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein-1; TNBC, triple negative breast cancer; UPS, undifferentiated pleomorphic sarcoma

View Currently Recruiting Trials

This site may contain information on an investigational agent(s) or investigational uses of approved agent(s) that has not been reviewed or approved by the FDA or other regulatory authorities. Iovance does not endorse or recommend any unapproved use of its products. Please refer to product prescribing information, where available.